L-citrulline to Improve Adverse Outcomes in Admitted Children (EChiLiBRiST, Clinical Trial 2, Inpatients)

Infections Clinical Trial

Official title:

A Randomised, Double-blind, Placebo-controlled Trial of L-Citrulline Oral Supplementation to Improve Short and Long-term Outcomes of Admitted Febrile Paediatric Patients With Biomarker-determined High-risk of Adverse Outcomes

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06426147
• Other study ID #: EChiLiBRiST CT2
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 1, 2025
• Est. completion date: April 1, 2027

Study information

• Verified date: May 2024
• Source: Barcelona Institute for Global Health
• Contact: Quique Bassat, Prof
• Phone: 93 227 92 12
• Email: quique.bassat[@]isglobal.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In low and middle-income countries, children admitted to hospital are not similarly ill, and do not all have a comparable prognosis. In fact, understanding at first encounter their risk of developing adverse outcomes (including mortality) could allow a more focused management and the tailoring of specific interventions to decrease in hospital mortality, and post discharge adverse longer-term outcomes. This clinical trial, part of the EChiLiBRiST larger project ("Development and validation of a quantitative point-of-care test for the measurement of severity biomarkers to improve risk stratification of fever syndromes and enhance child survival") has the two-fold objective of:

1. Assessing whether a POINT-OF-CARE rapid triaging test (PoC RTT) based on the quantitative measurement at the bedside of the "prognostic" biomarker sTREM-1 (soluble-triggering receptor expressed on myeloid cells 1) can reliably identify those admitted children with a higher risk of adverse outcomes; and

2. Assessing whether the therapeutic intervention (the L-arginine precursor, L-Citrulline, key in the nitric oxide biosynthesis), administered orally for 28 days to those children aged 1-<60 months identified as "moderate-to-high risk" by the prognostic biomarker can improve outcomes as compared to those receiving an indistinguishable placebo.

This second objective will be assessed in a prospective multi-country, multi-site, individually randomised, two-arm, placebo-controlled, double blind clinical trial involving ~888 children 1-<60m of age admitted to hospital and determined to be at high risk of adverse outcomes by their baseline sTREM-1 levels. The trial will compare the efficacy of a twice-daily dose of L-citrulline syrup vs placebo (200-300mg/kg/day depending on weight-band; for 28 days) in reducing adverse outcomes in children with severe disease. The trial will be running independently but in parallel in two high-mortality settings in Mozambique and in Ethiopia.

Description:

Children admitted to hospital and meeting the study eligibility criteria who are 0-<60 months of age will be eligible for study inclusion, and for initial biomarker screening using the study-designed rapid triaging PoC test, based on the measurement of sTREM-1. Study participants aged 1m-<5 years of age with sTREM-1 values classified as moderate (i.e., "yellow") or high-risk (i.e., "red") in the traffic light risk-stratification system will be randomly allocated (1:1) to receive L-Cit intervention or placebo. All study participants will be followed for 6 months, with study visits at the study hospitals or at home or via phone communication after discharge at day 3, day 5, day 7, day 28, and month 6. The study primary outcome will be "adverse disease outcome", defined as a composite of mortality, incident neurological sequelae, major adverse kidney event at discharge, need for organ support, clinical shock, coma, severe respiratory distress or need for readmission within 28 days after recruitment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 2200
• Est. completion date: April 1, 2027
• Est. primary completion date: January 1, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 0 Months to 60 Months

Eligibility

Inclusion Criteria:

• Enrolled in the initial prognostic screening component.

• Sick children with fever (axillary temperature>37.5ºC) or a history of fever (within the preceding 72h) or with suspected severe disease.

• 1m-<60 months of age.

• With an indication for admission, or having already been admitted to hospital due to their illness.

• With an sTREM-1 PoC result classifying their disease as of "moderate-high risk" ("yellow" or "red") upon study recruitment and within D3.

• Residents in the study area or willing to be contacted and traced during the study duration.

• Willing to sign an informed consent document.

• Willing to undergo and adhere to study procedures as explained in the IC document.

Exclusion Criteria:

• Admission to hospital for social reasons (and not on account of their disease).

• Children for which informed consent document has not been signed.

• Known allergy or contraindication to any of the study supplements including lactose intolerance or observing a lactose-free diet.

• Concurrent participation in any other clinical trial.

• Patient under NPO or "nothing by mouth" prescription .

• Contraindication for the insertion of a nasogastric tube (NGT) of for the enteral administration of drugs through the NGT in children who cannot tolerate by mouth.

• Critically sick patient whose prognosis is considered by the clinical researcher as fatal outcome in the following hours after screening.

• Any other condition determined by the investigators that makes it unlikely that the participant would complete the follow up until day 28 of study.

Related Conditions & MeSH terms

• Child, Only
• Communicable Diseases
• Infections
• Infectious Disease

Intervention

Dietary Supplement:
• L-citrulline
1 or 2 sachets every 12 hours (200-300mg/kg/day depending on weight-band) for 28 days
• Placebo
1 or 2 sachets every 12 hours (depending on weight-band) for 28 days

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Barcelona Institute for Global Health

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Concentration of circulating mediators of host immune and endothelial function, inflammation, intestinal barrier function, and neuronal damage	Concentration of circulating mediators of host immune and endothelial function, inflammation, intestinal barrier function, and neuronal damage at baseline, D3 and D7	Up to day 7
Other	Lactate levels	Levels of lactate at baseline and D3	Up to day 3
Other	Levels of markers of kidney function	Levels of markers of kidney function (creatinine, urea, saliva urea nitrogen (SUN), uNGAL etc.) at baseline, D3, D7 and at discharge	Up to day 7
Other	PoC-RTT prognostic performance	Prognostic performance of PoC-RTT measured sTREM-1 values at baseline among children (0-<60 months of age) with adverse outcomes up to D28.	Up to day 28
Other	Prognostic performance of a larger panel of biomarkers	Prognostic performance of a larger panel of prognostic biomarkers (circulating markers of endothelial function, inflammation, intestinal barrier function, and neuronal damage) at baseline.	At baseline
Primary	Adverse disease outcome	Proportion of participants with "adverse disease outcome" defined as a composite of (i.e., the occurrence between D0 and D28 after recruitment of at least one -or more- of the following adverse outcomes): Mortality; Incident neurological sequelae; Major adverse kidney event at discharge (MAKE-DC, defined as a severe AKI event between 2-7 days or a discharge eGFR<60mL/min per 1.73m2); Need for organ support; Clinical shock; Coma; Severe respiratory distress; Need for readmission within the first 28 days post-recruitment (after having been discharged)	Up to day 28
Secondary	Mortality	Proportion of participants with mortality between day 0 and day 28 after recruitment and/or up to hospital discharge.	Up to day 28
Secondary	Incident neurological sequelae	Proportion of participants with incident neurological sequelae between day 0 and day 28 after recruitment and/or up to hospital discharge.	Up to day 28
Secondary	Major adverse kidney event	Proportion of participants with major adverse kidney event at discharge (MAKE-DC, defined as a severe AKI event between 2-7 days or a discharge eGFR<60mL/min per 1.73m2)	Up to day 28
Secondary	Need for organ support	Proportion of participants with need for organ support	Up to day 28
Secondary	Clinical shock	Proportion of participants with clinical shock	Up to day 28
Secondary	Severe respiratory distress	Proportion of participants with severe respiratory distress	Up to day 28
Secondary	Coma	Proportion of participants with coma	Up to day 28
Secondary	Need for readmission	Proportion of participants with need for readmission within the first 28 days post-recruitment (after having been discharged)	Up to day 28
Secondary	Median duration of antibiotic treatment	Median duration of antibiotic treatment up to day 28	Up to day 28
Secondary	Oxygen requirement	Proportion of participants with oxygen requirement up to D28 and/or up to hospital discharge	Up to day 28
Secondary	Radiological pneumonia	Proportion of participants with radiological pneumonia among children with RTI up to D28 and/or up to hospital discharge	Up to day 28
Secondary	Hypoxemia (Sp02 <90%)	Proportion of participants with hypoxemia (Sat 02<90% irrespective of supplementary oxygen in absence of cyanotic heart disease) up to D28 and/or up to hospital discharge	Up to day 28
Secondary	Lenght of hospitalisation	Length of hospitalisation up to D28 and/or up to hospital discharge	Up to day 28
Secondary	Mortality	Proportion of participants with mortality up to M6	Up to month 6
Secondary	Secondary consultation or hospitalisations	Proportion of participants with secondary consultations or hospitalisations up to M6	Up to month 6
Secondary	Proportion of participants with serious adverse events	Proportion of participants with serious adverse events up to month 6	Up to month 6
Secondary	Proportion of participants with suspected unexpected serious adverse reactions	Proportion of participants with suspected unexpected serious adverse reactions up to M6.	Up to month 6
Secondary	Proportion of participants with adverse events	Proportion of participants with adverse events up to D30.	Up to day 30